+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Clinical effect and safety of liposomal-albendazole and tablet-albendazole for the treatment of human cystic echinococcosis



Clinical effect and safety of liposomal-albendazole and tablet-albendazole for the treatment of human cystic echinococcosis



Zhonghua Gan Zang Bing Za Zhi 19(7): 532-536



To explore and compare the clinical effect and safety of liposomal albendazole (L-ABZ) and tablet-albendazole (T-ABZ) in the treatment of cystic echinococcosis (CE1, CE2, and CE3). A total of 269 cases treated with cystic echinococcosis (CE) in Xinjiang Medical University the First Affiliated Hospital from 1998 to 2008 were reviewed. 51 cases were excluded and 218 cases were enrolled in this research by retrospective case-control method. Among 110 cases were treated with L-ABZ and 108 cases were treated with T-ABZ for short-term (3 months) and long-term courses (6 months) respectively. The effects and safety of the two medicines were compared by analyzing the clinical symptoms, imaging check and serologic test results. In short-term effect evaluation, the total effective rates and curative rates of L-ABZ group and T-ABZ group were 77.9% and 49.1% vs 28.4% and 13.9%, respectively. The effects of L-ABZ group was better than that of T-ABZ group, with remarkable difference in total effective rates and curative rates (x2 value was 19.581, 6.877, respectively, P is less than 0.05). In long-term effect evaluation, the total effective rates and curative rates of L-ABZ and T-ABZ group were 81.7% and 49.0% vs 47.6% and 20.6%, respectively. There was significant difference between L-ABZ group and T-ABZ group in total effective rates and curative rates (x2 value was 20.977, 15.049, respectively, P is less than 0.05). In T-ABZ group the short-term curative rates were 50.0% (15/30), 8.8% (8/91) and 33.3% (7/21) respectively in CE1, CE2, and CE3, the short-term total effective rates were 56.7% (17/30), 35.2% (32/91) and 61.9% (13/21) respectively in CE1, CE2, and CE3. The long-term curative rates were 58.3% (7/12), 28.6% (12/42) and 70.0% (7/10) respectively in CE1, CE2 and CE3, the long-term total effective rates were 75.0% (9/12), 69.0% (29/42) and 100.0% (10/10) respectively in CE1, CE2, and CE3. When compared with CE2, differences existed in CE1 (x2 = 24.887, 4.329; P is less than 0.05) and CE3 groups (x2 = 8.860, 5.076; P is less than 0.05) in terms of short-term effects. In L-ABZ group, the short-term curative rates were 47.4% (18/38), 12.2% (12/98) and 61.5% (8/13) respectively in CE1, CE2 and CE3, the short-term total effective rates were 92.1% (35/38), 65.3% (64/98) and 92.3% (12/13) respectively in CE1, CE2 and CE3, the long-term curative rates were 79.3% (23/29), 35.9% (23/64) and 50.0% (3/6) respectively in CE1, CE2 and CE3, the long-term total effective rates were 96.6% (28/29), 84.4% (54/64) and 100% (6/6) respectively in CE1, CE2 and CE3. When compared with CE2, there were significant differences in CE1 (x2 = 19.648, 9.930; P is less than 0.05) and CE3 groups (x2 = 18.880, 3.876; P is less than 0.05) in terms of short-term effect. In L-ABZ and T-ABZ groups, the drug-related adverse effects were 11.1% (12/108) and 12.7% (14/110) respectively without significant difference (x2 = 0.155, P is more than 0.05). L-ABZ and T-ABZ were both effective anti-echinococcosis drugs without dominant side-effects. The clinical effect of L-ABZ was better than that of T-ABZ.

(PDF emailed within 1 workday: $29.90)

Accession: 052114581

Download citation: RISBibTeXText

PMID: 22152246


Related references

Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial. Medicine 95(4): E2237, 2016

Investigation on blood concentrations of albendazole sulfoxides in patients with cystic echinococcosis treated by emulsion albendazole. Endemic Diseases Bulletin 16(3): 64-66, 2001

Albendazole treatment of human cystic echinococcosis. Transactions of the Royal Society of Tropical Medicine and Hygiene 82(3): 453-459, 1988

Therapeutic drug monitoring of albendazole: determination of albendazole, albendazole sulfoxide, and albendazole sulfone in human plasma using nonaqueous capillary electrophoresis. Electrophoresis 21(4): 729-736, 2000

Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Tropica 64(1-2): 79-93, 1997

Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Tropica 64(1/2): 79-93, 1996

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations. Parasitology Research 103(2): 355-362, 2008

Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis. Annals of Tropical Medicine and Parasitology 88(1): 49-52, 1994

A comparative trial of clinical efficacy of emulsion albendazole in treatment of hepatic cystic echinococcosis. Chinese Journal of Parasitic Disease Control 15(4): 228-229, 2002

In vivo effect of oral albendazole and albendazole sulphoxide on development of secondary echinococcosis in mice. International Journal for Parasitology 27(11): 1341-1345, 1998

Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. Acta Tropica 83(2): 177-181, 2002

Japanese monkey (Macaca fuscata) with alveolar echinococcosis after treatment with albendazole for 10 years: serodiagnosis and determination of albendazole metabolites. Parasitology Research 106(1): 69-74, 2010

Human cystic echinococcosis response to Albendazole and Praziquantel chemotherapy Clinical, imagistic and humoral immune evalution. American Journal of Tropical Medicine & Hygiene 61(3 SUPPL ): 241-242, Sept, 1999

Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. American Journal of the Medical Sciences 334(3): 171-179, 2007

Experience with Albendazole Treatment in Children with Cystic Echinococcosis. Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2017(2): 9-13, 2017